MRE11 expression is predictive of cause-specific survival following radical radiotherapy for muscle-invasive bladder cancer.

Radical radiotherapy and surgery achieve similar cure rates in muscle-invasive bladder cancer, but the choice of which treatment would be most beneficial cannot currently be predicted for individual patients. The primary aim of this study was to assess whether expression of any of a panel of DNA damage signaling proteins in tumor samples taken before irradiation could be used as a predictive marker of radiotherapy response, or rather was prognostic. Protein expression of MRE11, RAD50, NBS1, ATM, and H2AX was studied by immunohistochemistry in pretreatment tumor specimens from two cohorts of bladder cancer patients (validation cohort prospectively acquired) treated with radical radiotherapy and one cohort of cystectomy patients. In the radiotherapy test cohort (n = 86), low tumor MRE11 expression was associated with worse cancer-specific survival compared with high expression [43.1% versus 68.7% 3-year cause-specific survival (CSS), P = 0.012] by Kaplan-Meier analysis. This was confirmed in the radiotherapy validation cohort (n = 93; 43.0% versus 71.2%, P = 0.020). However, in the cystectomy cohort (n = 88), MRE11 expression was not associated with cancer-specific survival, commensurate with MRE11 being a predictive marker. High MRE11 expression in the combined radiotherapy cohort had a significantly better cancer-specific survival compared with the high-expression cystectomy cohort (69.9% versus 53.8% 3-year CSS, P = 0.021). In this validated immunohistochemistry study, MRE11 protein expression was shown and confirmed as a predictive factor associated with survival following bladder cancer radiotherapy, justifying its inclusion in subsequent trial designs. MRE11 expression may ultimately allow patient selection for radiotherapy or cystectomy, thus improving overall cure rates.

[1]  J. Overgaard,et al.  The possible role of TP53 mutation status in the treatment of squamous cell carcinomas of the head and neck (HNSCC) with radiotherapy with different overall treatment times. , 2005, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[2]  P. Hall,et al.  Assessing p53 in clinical contexts: unlearned lessons and new perspectives , 2006, The Journal of pathology.

[3]  Thierry Soussi,et al.  Somatic point mutations in the p53 gene of human tumors and cell lines: updated compilation , 1996, Nucleic Acids Res..

[4]  J. Bartek,et al.  The DNA-damage response in human biology and disease , 2009, Nature.

[5]  A. Hart,et al.  Apoptosis, proliferation and p53, cyclin D1, and retinoblastoma gene expression in relation to radiation response in transitional cell carcinoma of the bladder. , 2001, International journal of radiation oncology, biology, physics.

[6]  R. Bergström,et al.  p53 and Rb immunostaining in locally advanced bladder cancer: relation to prognostic variables and predictive value for the local response to radical radiotherapy. , 1995, European urology.

[7]  S. Fosså,et al.  p53, p21 and mdm2 expression vs the response to radiotherapy in transitional cell carcinoma of the bladder , 2001, BJU international.

[8]  I. Tannock,et al.  Long-term outcome of radiation-based conservation therapy for invasive bladder cancer. , 2007, Urologic oncology.

[9]  C. Rödel,et al.  Apoptosis, p53, bcl-2, and Ki-67 in invasive bladder carcinoma: possible predictors for response to radiochemotherapy and successful bladder preservation. , 2000, International journal of radiation oncology, biology, physics.

[10]  D. Lane,et al.  P53 abnormalities and outcomes in colorectal cancer: a systematic review , 2005, British Journal of Cancer.

[11]  A. Gown.  Current issues in ER and HER2 testing by IHC in breast cancer , 2008, Modern Pathology.

[12]  J. Ribeiro,et al.  Relationship between radiation response and p53 status in human bladder cancer cells. , 1997, International journal of radiation biology.

[13]  Samantha Sharpe,et al.  Cancer Research UK , 2002, Nature Cell Biology.

[14]  M. Lavin.  ATM and the Mre11 complex combine to recognize and signal DNA double-strand breaks , 2007, Oncogene.

[15]  A. Kiltie,et al.  APE1 and XRCC1 Protein Expression Levels Predict Cancer-Specific Survival Following Radical Radiotherapy in Bladder Cancer , 2005, Clinical Cancer Research.

[16]  H. Liber,et al.  NBS1 knockdown by small interfering RNA increases ionizing radiation mutagenesis and telomere association in human cells. , 2005, Cancer research.

[17]  G. Bussolati,et al.  Technical pitfalls potentially affecting diagnoses in immunohistochemistry , 2008, Journal of Clinical Pathology.

[18]  Xiao-Feng Sun,et al.  ATM expression in rectal cancers with or without preoperative radiotherapy. , 2005, Oncology reports.

[19]  L. Skoog,et al.  Intact Mre11/Rad50/Nbs1 complex predicts good response to radiotherapy in early breast cancer. , 2007, International journal of radiation oncology, biology, physics.

[20]  M. Suntharalingam,et al.  Radiosensitization of head/neck squamous cell carcinoma by adenovirus-mediated expression of the Nbs1 protein. , 2007, International journal of radiation oncology, biology, physics.

[21]  R. Huddart,et al.  SPARE: A qualitative study investigating randomization barriers in a Selective Bladder Preservation trial (SBP) (ISCRCTN: 61126465). , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  J. Mellon,et al.  Improving and predicting radiosensitivity in muscle invasive bladder cancer. , 2003, The Journal of urology.

[23]  I. N. Reid,et al.  A hot spot for p53 mutation in transitional cell carcinoma of the bladder: clues to the etiology of bladder cancer. , 1997, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[24]  A. Kiltie,et al.  Similar treatment outcomes for radical cystectomy and radical radiotherapy in invasive bladder cancer treated at a United Kingdom specialist treatment center. , 2008, International journal of radiation oncology, biology, physics.

[25]  D. Neal,et al.  Combined p21WAF1/CIP1 and p53 overexpression predict improved survival in muscle-invasive bladder cancer treated by radical radiotherapy. , 2001, International journal of radiation oncology, biology, physics.

[26]  I. Runnebaum,et al.  Association of p53 mutations and a codon 72 single nucleotide polymorphism with lower overall survival and responsiveness to adjuvant radiotherapy in endometrioid endometrial carcinomas , 2005, International Journal of Gynecologic Cancer.

[27]  H. Tauchi,et al.  Dancing on damaged chromatin: functions of ATM and the RAD50/MRE11/NBS1 complex in cellular responses to DNA damage. , 2008, Journal of radiation research.

[28]  A. Gotoh,et al.  Radiation induces p53-dependent cell apoptosis in bladder cancer cells with wild-type-p53 but not in p53-mutated bladder cancer cells , 2003, Urological Research.

[29]  M. Oren,et al.  Decision making by p53: life, death and cancer , 2003, Cell Death and Differentiation.

[30]  M. Olivier,et al.  Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database , 2007, Human mutation.

[31]  C. Cordon-Cardo.  p53 and RB: simple interesting correlates or tumor markers of critical predictive nature? , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  S. Fosså,et al.  Prognostic factors in muscle-invasive bladder cancer treated with radiotherapy: an immunohistochemical study. , 1998, British journal of urology.

[33]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2007, Archives of pathology & laboratory medicine.

[34]  B. Czerniak,et al.  Prognostic value of p53 in muscle-invasive bladder cancer treated with preoperative radiotherapy. , 1996, Urology.

[35]  D. Hwang,et al.  Gastrosplenic fistula from Hodgkin's lymphoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  Alessandra Viel,et al.  Human MRE11 is inactivated in mismatch repair‐deficient cancers , 2002, EMBO reports.

[37]  G. Capellá,et al.  p53 and p21 expression levels predict organ preservation and survival in invasive bladder carcinoma treated with a combined‐modality approach , 2004, Cancer.

[38]  G. Kerr,et al.  Radical radiotherapy and salvage cystectomy as the primary management of transitional cell carcinoma of the bladder. Results following the introduction of a CT planning technique. , 2002, Clinical oncology (Royal College of Radiologists (Great Britain)).